{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:46:26Z","timestamp":1761767186995,"version":"3.37.3"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-023-04330-1","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:02:55Z","timestamp":1678539775000},"page":"3205-3230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-1005","authenticated-orcid":false,"given":"Ugo","family":"Pinar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Calleris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Grobet-Jeandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Benamran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"4330_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"4330_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35:379\u2013387. https:\/\/doi.org\/10.1007\/s00345-016-1928-x","journal-title":"World J Urol"},{"key":"4330_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1464-410X.2009.08818.x","volume":"105","author":"G Lughezzani","year":"2010","unstructured":"Lughezzani G, Jeldres C, Isbarn H et al (2010) Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU Int 105:799\u2013804. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08818.x","journal-title":"BJU Int"},{"key":"4330_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224\u20131233. https:\/\/doi.org\/10.1002\/cncr.24135","journal-title":"Cancer"},{"key":"4330_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111\u2013122. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"key":"4330_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66:42\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.033","journal-title":"Eur Urol"},{"key":"4330_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(14)71160-X","journal-title":"Lancet Oncol"},{"key":"4330_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","volume":"189","author":"DA Green","year":"2013","unstructured":"Green DA, Rink M, Xylinas E et al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189:1214\u20131221. https:\/\/doi.org\/10.1016\/j.juro.2012.05.079","journal-title":"J Urol"},{"key":"4330_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00345-013-1116-1","volume":"32","author":"P Colin","year":"2014","unstructured":"Colin P, Ghoneim TP, Nison L et al (2014) Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. World J Urol 32:507\u2013512. https:\/\/doi.org\/10.1007\/s00345-013-1116-1","journal-title":"World J Urol"},{"key":"4330_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581\u2013587. https:\/\/doi.org\/10.1016\/j.eururo.2010.06.029","journal-title":"Eur Urol"},{"key":"4330_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","volume":"112","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Rink M, Margulis V et al (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112:453\u2013461. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11649.x","journal-title":"BJU Int"},{"key":"4330_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bju.12597","volume":"114","author":"M Kaag","year":"2014","unstructured":"Kaag M, Trost L, Thompson RH et al (2014) Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int 114:674\u2013679. https:\/\/doi.org\/10.1111\/bju.12597","journal-title":"BJU Int"},{"key":"4330_CR13","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet Lond Engl 395:1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3","journal-title":"Lancet Lond Engl"},{"key":"4330_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000282755","volume":"55","author":"M Igawa","year":"1995","unstructured":"Igawa M, Urakami S, Shiina H et al (1995) Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 55:74\u201377","journal-title":"Urol Int"},{"key":"4330_CR15","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/cncr.25050","volume":"116","author":"SF Matin","year":"2010","unstructured":"Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127\u20133134. https:\/\/doi.org\/10.1002\/cncr.25050","journal-title":"Cancer"},{"key":"4330_CR16","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.28655","volume":"120","author":"S Porten","year":"2014","unstructured":"Porten S, Siefker-Radtke AO, Xiao L et al (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120:1794\u20131799. https:\/\/doi.org\/10.1002\/cncr.28655","journal-title":"Cancer"},{"key":"4330_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clgc.2021.12.014","volume":"20","author":"M Adibi","year":"2022","unstructured":"Adibi M, McCormick B, Economides MP et al (2022) Five and ten-year outcomes of neoadjuvant chemotherapy and surgery for high-risk upper tract urothelial carcinoma. Clin Genitourin Cancer 20:176\u2013182. https:\/\/doi.org\/10.1016\/j.clgc.2021.12.014","journal-title":"Clin Genitourin Cancer"},{"key":"4330_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","volume":"200","author":"RS Liao","year":"2018","unstructured":"Liao RS, Gupta M, Schwen ZR et al (2018) Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol 200:68\u201373. https:\/\/doi.org\/10.1016\/j.juro.2017.12.054","journal-title":"J Urol"},{"key":"4330_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.01.058","author":"X Meng","year":"2019","unstructured":"Meng X, Chao B, Vijay V et al (2019) High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma. Urology. https:\/\/doi.org\/10.1016\/j.urology.2019.01.058","journal-title":"Urology"},{"key":"4330_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.04.025","author":"N Singla","year":"2020","unstructured":"Singla N, Christie A, Freifeld Y et al (2020) Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2020.04.025","journal-title":"Urol Oncol"},{"key":"4330_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","volume":"4","author":"S Hosogoe","year":"2018","unstructured":"Hosogoe S, Hatakeyama S, Kusaka A et al (2018) Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 4:946\u2013953. https:\/\/doi.org\/10.1016\/j.euf.2017.03.013","journal-title":"Eur Urol Focus"},{"key":"4330_CR22","doi-asserted-by":"publisher","first-page":"101500","DOI":"10.18632\/oncotarget.21551","volume":"8","author":"Y Kubota","year":"2017","unstructured":"Kubota Y, Hatakeyama S, Tanaka T et al (2017) Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 8:101500\u2013101508. https:\/\/doi.org\/10.18632\/oncotarget.21551","journal-title":"Oncotarget"},{"key":"4330_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10010010","author":"M Miyake","year":"2019","unstructured":"Miyake M, Marugami N, Fujiwara Y et al (2019) Down-grading of ipsilateral hydronephrosis by neoadjuvant chemotherapy correlates with favorable oncological outcomes in patients undergoing radical nephroureterectomy for ureteral carcinoma. Diagn Basel Switz. https:\/\/doi.org\/10.3390\/diagnostics10010010","journal-title":"Diagn Basel Switz"},{"key":"4330_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15230","author":"K Zennami","year":"2020","unstructured":"Zennami K, Sumitomo M, Takahara K et al (2020) Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma. BJU Int. https:\/\/doi.org\/10.1111\/bju.15230","journal-title":"BJU Int"},{"key":"4330_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bju.15346","volume":"128","author":"T Hamaya","year":"2021","unstructured":"Hamaya T, Hatakeyama S, Tanaka T et al (2021) Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study. BJU Int 128:468\u2013476. https:\/\/doi.org\/10.1111\/bju.15346","journal-title":"BJU Int"},{"key":"4330_CR26","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1245\/s10434-019-08128-7","volume":"27","author":"L Chen","year":"2020","unstructured":"Chen L, Ou Z, Wang R et al (2020) Neoadjuvant chemotherapy benefits survival in high-grade upper tract urothelial carcinoma: a propensity score-based analysis. Ann Surg Oncol 27:1297\u20131303. https:\/\/doi.org\/10.1245\/s10434-019-08128-7","journal-title":"Ann Surg Oncol"},{"key":"4330_CR27","doi-asserted-by":"publisher","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","volume":"16","author":"N Almassi","year":"2018","unstructured":"Almassi N, Gao T, Lee B et al (2018) Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery. Clin Genitourin Cancer 16:e1237\u2013e1242. https:\/\/doi.org\/10.1016\/j.clgc.2018.08.003","journal-title":"Clin Genitourin Cancer"},{"key":"4330_CR28","first-page":"9938","volume":"26","author":"F Davaro","year":"2019","unstructured":"Davaro F, May A, McFerrin C et al (2019) Chemotherapy increases survival and downstaging of upper tract urothelial cancer. Can J Urol 26:9938\u20139944","journal-title":"Can J Urol"},{"key":"4330_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14719","author":"A Martini","year":"2019","unstructured":"Martini A, Daza J, Poltiyelova E et al (2019) Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU Int. https:\/\/doi.org\/10.1111\/bju.14719","journal-title":"BJU Int"},{"key":"4330_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/JU.0000000000000737","volume":"203","author":"B Foerster","year":"2020","unstructured":"Foerster B, Abufaraj M, Petros F et al (2020) Efficacy of preoperative chemotherapy for high risk upper tract urothelial carcinoma. J Urol 203:1101\u20131108. https:\/\/doi.org\/10.1097\/JU.0000000000000737","journal-title":"J Urol"},{"key":"4330_CR31","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/bju.15253","volume":"127","author":"D D\u2019Andrea","year":"2021","unstructured":"D\u2019Andrea D, Matin S, Black PC et al (2021) Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int 127:528\u2013537. https:\/\/doi.org\/10.1111\/bju.15253","journal-title":"BJU Int"},{"key":"4330_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euros.2020.04.001","volume":"19","author":"D D\u2019Andrea","year":"2020","unstructured":"D\u2019Andrea D, Foerster B, Matin SF et al (2020) Impact of sex on response to neoadjuvant chemotherapy in patients with upper-tract urothelial cancer. Eur Urol Open Sci 19:16\u201319. https:\/\/doi.org\/10.1016\/j.euros.2020.04.001","journal-title":"Eur Urol Open Sci"},{"key":"4330_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.clgc.2022.01.004","volume":"20","author":"NC Grossmann","year":"2022","unstructured":"Grossmann NC, Pradere B, D\u2019Andrea D et al (2022) Neoadjuvant chemotherapy in elderly patients with upper tract urothelial cancer: oncologic outcomes from a multicenter study. Clin Genitourin Cancer 20:227\u2013236. https:\/\/doi.org\/10.1016\/j.clgc.2022.01.004","journal-title":"Clin Genitourin Cancer"},{"key":"4330_CR34","doi-asserted-by":"publisher","first-page":"788.e15","DOI":"10.1016\/j.urolonc.2021.05.037","volume":"39","author":"RA Ghandour","year":"2021","unstructured":"Ghandour RA, Freifeld Y, Cheaib J et al (2021) Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urol Oncol 39:788.e15-788.e21. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.037","journal-title":"Urol Oncol"},{"key":"4330_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/JU.0000000000000644","volume":"203","author":"V Margulis","year":"2020","unstructured":"Margulis V, Puligandla M, Trabulsi EJ et al (2020) Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J Urol 203:690\u2013698. https:\/\/doi.org\/10.1097\/JU.0000000000000644","journal-title":"J Urol"},{"key":"4330_CR36","first-page":"2","volume":"2","author":"JA Coleman","year":"2019","unstructured":"Coleman JA, Wong NC, Sjoberg DD et al (2019) Multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. J Urol 2:2","journal-title":"J Urol"},{"key":"4330_CR37","first-page":"230","volume":"2","author":"AO Siefker-Radtke","year":"2012","unstructured":"Siefker-Radtke AO, Kamat AM, Corn PG et al (2012) Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M.D Anderson Cancer Center. J Clin Oncol 2:230\u2013261","journal-title":"J Clin Oncol"},{"key":"4330_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/cncr.27751","volume":"119","author":"AO Siefker-Radtke","year":"2013","unstructured":"Siefker-Radtke AO, Dinney CP, Shen Y et al (2013) A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119:540\u2013547. https:\/\/doi.org\/10.1002\/cncr.27751","journal-title":"Cancer"},{"key":"4330_CR39","unstructured":"Neoadjuvant chemotherapy versus surgery alone in patients with high-grade UTUC\u2014full text view\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT***02876861. Accessed 5 Jul 2019"},{"key":"4330_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1442-2042.2004.00841.x","volume":"11","author":"S Suzuki","year":"2004","unstructured":"Suzuki S, Shinohara N, Harabayashi T et al (2004) Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int J Urol Off J Jpn Urol Assoc 11:456\u2013460. https:\/\/doi.org\/10.1111\/j.1442-2042.2004.00841.x","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"4330_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.urology.2006.01.053","volume":"68","author":"C Kwak","year":"2006","unstructured":"Kwak C, Lee SE, Jeong IG, Ku JH (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68:53\u201357. https:\/\/doi.org\/10.1016\/j.urology.2006.01.053","journal-title":"Urology"},{"key":"4330_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.juro.2015.03.077","volume":"194","author":"Y-C Huang","year":"2015","unstructured":"Huang Y-C, Chen M-F, Shi C-S et al (2015) The Efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma. J Urol 194:323\u2013329. https:\/\/doi.org\/10.1016\/j.juro.2015.03.077","journal-title":"J Urol"},{"key":"4330_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3892\/ol.2018.9672","volume":"17","author":"Y-H Chang","year":"2019","unstructured":"Chang Y-H, Hsiao P-J, Chen G-H et al (2019) Outcomes of stage II-IV upper-tract urothelial carcinoma and adjuvant chemotherapy for locally advanced cancer. Oncol Lett 17:1341\u20131348. https:\/\/doi.org\/10.3892\/ol.2018.9672","journal-title":"Oncol Lett"},{"key":"4330_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijsu.2019.04.013","volume":"66","author":"W Song","year":"2019","unstructured":"Song W, Jeong JY, Jeon HG et al (2019) Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: a retrospective cohort study. Int J Surg Lond Engl 66:12\u201317. https:\/\/doi.org\/10.1016\/j.ijsu.2019.04.013","journal-title":"Int J Surg Lond Engl"},{"key":"4330_CR45","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.3892\/ol.2019.10086","volume":"17","author":"T Narimatsu","year":"2019","unstructured":"Narimatsu T, Kambara T, Abe H et al (2019) 5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase. Oncol Lett 17:4429\u20134436. https:\/\/doi.org\/10.3892\/ol.2019.10086","journal-title":"Oncol Lett"},{"key":"4330_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4111\/kju.2015.56.1.41","volume":"56","author":"KS Lee","year":"2015","unstructured":"Lee KS, Kim KH, Yoon YE et al (2015) Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy. Korean J Urol 56:41\u201347. https:\/\/doi.org\/10.4111\/kju.2015.56.1.41","journal-title":"Korean J Urol"},{"key":"4330_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00345-011-0775-z","volume":"30","author":"A Kawashima","year":"2012","unstructured":"Kawashima A, Nakai Y, Nakayama M et al (2012) The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study. World J Urol 30:701\u2013706. https:\/\/doi.org\/10.1007\/s00345-011-0775-z","journal-title":"World J Urol"},{"key":"4330_CR48","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.juro.2014.10.022","volume":"193","author":"S Shirotake","year":"2015","unstructured":"Shirotake S, Kikuchi E, Tanaka N et al (2015) Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience. J Urol 193:1122\u20131128. https:\/\/doi.org\/10.1016\/j.juro.2014.10.022","journal-title":"J Urol"},{"key":"4330_CR49","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/iju.12868","volume":"22","author":"K Fujita","year":"2015","unstructured":"Fujita K, Inamoto T, Yamamoto Y et al (2015) Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: a multi-institutional, retrospective study. Int J Urol Off J Jpn Urol Assoc 22:1006\u20131012. https:\/\/doi.org\/10.1111\/iju.12868","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"4330_CR50","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00345-017-2032-6","volume":"35","author":"T Nakagawa","year":"2017","unstructured":"Nakagawa T, Komemushi Y, Kawai T et al (2017) Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol 35:1569\u20131575. https:\/\/doi.org\/10.1007\/s00345-017-2032-6","journal-title":"World J Urol"},{"key":"4330_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12894-017-0305-4","volume":"17","author":"K Fujita","year":"2017","unstructured":"Fujita K, Taneishi K, Inamoto T et al (2017) Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 17:110. https:\/\/doi.org\/10.1186\/s12894-017-0305-4","journal-title":"BMC Urol"},{"key":"4330_CR52","doi-asserted-by":"publisher","first-page":"e669","DOI":"10.1016\/j.clgc.2017.10.014","volume":"16","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Matsumoto K, Hirayama T et al (2018) Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for adjuvant chemotherapy: a multi-institutional retrospective study. Clin Genitourin Cancer 16:e669\u2013e675. https:\/\/doi.org\/10.1016\/j.clgc.2017.10.014","journal-title":"Clin Genitourin Cancer"},{"key":"4330_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03118-x","author":"T Matsunaga","year":"2020","unstructured":"Matsunaga T, Komura K, Hashimoto T et al (2020) Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort. World J Urol. https:\/\/doi.org\/10.1007\/s00345-020-03118-x","journal-title":"World J Urol"},{"key":"4330_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bju.12801","volume":"116","author":"I Lucca","year":"2015","unstructured":"Lucca I, Kassouf W, Kapoor A et al (2015) The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU Int 116:72\u201378. https:\/\/doi.org\/10.1111\/bju.12801","journal-title":"BJU Int"},{"key":"4330_CR55","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","volume":"35","author":"T Seisen","year":"2017","unstructured":"Seisen T, Krasnow RE, Bellmunt J et al (2017) Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 35:852\u2013860. https:\/\/doi.org\/10.1200\/JCO.2016.69.4141","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4330_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3238","author":"Z Liu","year":"2020","unstructured":"Liu Z, Huang J, Li X et al (2020) The effectiveness of chemotherapy for patients with pT3N0M0 renal pelvic urothelial carcinomas: an inverse probability of treatment weighting comparison using surveillance, epidemiology, and end results data. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.3238","journal-title":"Cancer Med"},{"key":"4330_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/jpm12020226","volume":"12","author":"C-Y Lin","year":"2022","unstructured":"Lin C-Y, Weng H-Y, Tai T-Y et al (2022) Clinical efficacy of adjuvant chemotherapy in advanced upper tract urothelial carcinoma (pT3-T4): real-world data from the Taiwan upper tract urothelial carcinoma collaboration group. J Pers Med 12:226. https:\/\/doi.org\/10.3390\/jpm12020226","journal-title":"J Pers Med"},{"key":"4330_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000092930","volume":"77","author":"SE Lee","year":"2006","unstructured":"Lee SE, Byun S-S, Park YH et al (2006) Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 77:22\u201326. https:\/\/doi.org\/10.1159\/000092930","journal-title":"Urol Int"},{"key":"4330_CR59","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1590\/S1677-5538.IBJU.2015.0009","volume":"41","author":"HS Kim","year":"2015","unstructured":"Kim HS, Lee JS, Jeong CW et al (2015) Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experience. Int Braz J Urol Off J Braz Soc Urol 41:1067\u20131079","journal-title":"Int Braz J Urol Off J Braz Soc Urol"},{"key":"4330_CR60","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","volume":"15","author":"N Soga","year":"2008","unstructured":"Soga N, Arima K, Sugimura Y (2008) Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol Off J Jpn Urol Assoc 15:800\u2013803. https:\/\/doi.org\/10.1111\/j.1442-2042.2008.02114.x","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"4330_CR61","doi-asserted-by":"publisher","first-page":"686","DOI":"10.7150\/jca.7326","volume":"4","author":"TS Kim","year":"2013","unstructured":"Kim TS, Oh JH, Rhew HY (2013) The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer 4:686\u2013690. https:\/\/doi.org\/10.7150\/jca.7326","journal-title":"J Cancer"},{"key":"4330_CR62","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.7150\/jca.34103","volume":"10","author":"M Kang","year":"2019","unstructured":"Kang M, Yoo H, Kim K et al (2019) Role of adjuvant chemotherapy in advanced stage upper urinary tract urothelial carcinoma after radical nephroureterectomy: competing risk analysis after propensity score-matching. J Cancer 10:6896\u20136902. https:\/\/doi.org\/10.7150\/jca.34103","journal-title":"J Cancer"},{"key":"4330_CR63","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","volume":"182","author":"NJ Hellenthal","year":"2009","unstructured":"Hellenthal NJ, Shariat SF, Margulis V et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the upper tract urothelial carcinoma collaboration. J Urol 182:900\u2013906. https:\/\/doi.org\/10.1016\/j.juro.2009.05.011","journal-title":"J Urol"},{"key":"4330_CR64","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1002\/cncr.26172","volume":"117","author":"M Vassilakopoulou","year":"2011","unstructured":"Vassilakopoulou M, de la Motte RT, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117:5500\u20135508. https:\/\/doi.org\/10.1002\/cncr.26172","journal-title":"Cancer"},{"key":"4330_CR65","doi-asserted-by":"publisher","first-page":"31.e17","DOI":"10.1016\/j.urolonc.2012.11.014","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, Tanguay S, Rendon R et al (2014) Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 32:31.e17\u201324. https:\/\/doi.org\/10.1016\/j.urolonc.2012.11.014","journal-title":"Urol Oncol"},{"key":"4330_CR66","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ijrobp.2019.03.027","volume":"104","author":"M Kim","year":"2019","unstructured":"Kim M, Kim JK, Lee J et al (2019) Adjuvant treatments for advanced stage, non-metastatic upper tract urothelial carcinoma: a multicenter study. Int J Radiat Oncol Biol Phys 104:819\u2013827. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4330_CR67","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bju.14020","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi A, Lo Vullo S, Mariani L et al (2018) Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of urology-young academic urologists and the upper tract urothelial carcinoma collaboration. BJU Int 121:252\u2013259. https:\/\/doi.org\/10.1111\/bju.14020","journal-title":"BJU Int"},{"key":"4330_CR68","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1200\/JCO.2004.09.043","volume":"22","author":"A Bamias","year":"2004","unstructured":"Bamias A, Deliveliotis C, Fountzilas G et al (2004) Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 22:2150\u20132154. https:\/\/doi.org\/10.1200\/JCO.2004.09.043","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4330_CR69","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3760\/cma.j.issn.0376-2491.40.007","volume":"99","author":"Y Luo","year":"2019","unstructured":"Luo Y, Feng BF, Wei DC et al (2019) Prospective controlled observation ofeffect of adjuvant chemotherapy onsurvival and prognosis ofhigh-risk upper tract urothelial carcinoma patients underwent radical nephroureterectomy. Zhonghua Yi Xue Za Zhi 99:3158\u20133163. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.40.007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"4330_CR70","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP et al (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.003","journal-title":"Eur Urol"},{"key":"4330_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.003","author":"JJ Leow","year":"2020","unstructured":"Leow JJ, Chong YL, Chang SL et al (2020) Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","journal-title":"Eur Urol"},{"key":"4330_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.06.108","author":"AI Khan","year":"2020","unstructured":"Khan AI, Taylor BL, Awamlh BAHA et al (2020) Survival outcomes in neoadjuvant chemotherapy for high grade upper tract urothelial carcinoma: a nationally representative analysis. Urology. https:\/\/doi.org\/10.1016\/j.urology.2020.06.108","journal-title":"Urology"},{"key":"4330_CR73","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/j.1464-410X.2011.10075.x","volume":"108","author":"RF Youssef","year":"2011","unstructured":"Youssef RF, Shariat SF, Lotan Y et al (2011) Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the upper tract urothelial carcinoma collaboration. BJU Int 108:1286\u20131291. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10075.x","journal-title":"BJU Int"},{"key":"4330_CR74","doi-asserted-by":"crossref","unstructured":"Hoffman-Censits J, Puligandla M, Trabulsi E, et al (2018) Phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinma (HG UTUC): results from ECOG-ACRIN 8141. J Urol e1166\u20137","DOI":"10.1016\/j.juro.2018.03.098"},{"key":"4330_CR75","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/jjco\/hys166","volume":"42","author":"H Kitamura","year":"2012","unstructured":"Kitamura H, Igarashi M, Tanaka T et al (2012) A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy. Jpn J Clin Oncol 42:1192\u20131196. https:\/\/doi.org\/10.1093\/jjco\/hys166","journal-title":"Jpn J Clin Oncol"},{"key":"4330_CR76","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.juro.2010.03.142","volume":"184","author":"V Margulis","year":"2010","unstructured":"Margulis V, Youssef RF, Karakiewicz PI et al (2010) Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 184:453\u2013458. https:\/\/doi.org\/10.1016\/j.juro.2010.03.142","journal-title":"J Urol"},{"key":"4330_CR77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.juro.2010.03.030","volume":"184","author":"JC Brien","year":"2010","unstructured":"Brien JC, Shariat SF, Herman MP et al (2010) Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 184:69\u201373. https:\/\/doi.org\/10.1016\/j.juro.2010.03.030","journal-title":"J Urol"},{"key":"4330_CR78","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1464-410X.2011.10288.x","volume":"109","author":"RL Favaretto","year":"2012","unstructured":"Favaretto RL, Shariat SF, Savage C et al (2012) Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int 109:77\u201382. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10288.x","journal-title":"BJU Int"},{"key":"4330_CR79","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bju.12238","volume":"112","author":"X-P Chen","year":"2013","unstructured":"Chen X-P, Xiong G-Y, Li X-S et al (2013) Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 112:917\u2013924. https:\/\/doi.org\/10.1111\/bju.12238","journal-title":"BJU Int"},{"key":"4330_CR80","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.urology.2011.02.038","volume":"78","author":"AK Smith","year":"2011","unstructured":"Smith AK, Stephenson AJ, Lane BR et al (2011) Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 78:82\u201386. https:\/\/doi.org\/10.1016\/j.urology.2011.02.038","journal-title":"Urology"},{"key":"4330_CR81","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.juro.2018.02.002","volume":"199","author":"EJ Margolin","year":"2018","unstructured":"Margolin EJ, Matulay JT, Li G et al (2018) Discordance between ureteroscopic biopsy and final pathology for upper tract urothelial carcinoma. J Urol 199:1440\u20131445. https:\/\/doi.org\/10.1016\/j.juro.2018.02.002","journal-title":"J Urol"},{"key":"4330_CR82","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fonc.2020.00481","volume":"10","author":"T-S Zhai","year":"2020","unstructured":"Zhai T-S, Jin L, Feng L-M et al (2020) Perioperative chemotherapy on survival in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy: a population-based study. Front Oncol 10:2","journal-title":"Front Oncol"},{"key":"4330_CR83","doi-asserted-by":"publisher","first-page":"684.e9","DOI":"10.1016\/j.urolonc.2020.03.008","volume":"38","author":"A Martini","year":"2020","unstructured":"Martini A, Falagario UG, Waingankar N et al (2020) Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma. Urol Oncol 38:684.e9-684.e15. https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.008","journal-title":"Urol Oncol"},{"key":"4330_CR84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.18.01148","journal-title":"J Clin Oncol"},{"key":"4330_CR85","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ et al (2022) Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 82:212\u2013222. https:\/\/doi.org\/10.1016\/j.eururo.2022.04.013","journal-title":"Eur Urol"},{"key":"4330_CR86","doi-asserted-by":"publisher","first-page":"10.e1","DOI":"10.1016\/j.urolonc.2021.05.014","volume":"40","author":"A Necchi","year":"2022","unstructured":"Necchi A, Martini A, Raggi D et al (2022) A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol 40:10.e1-10.e6. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.014","journal-title":"Urol Oncol"},{"key":"4330_CR87","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04330-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T09:06:40Z","timestamp":1699434400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":87,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["4330"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04330-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"9 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"For this study, oral consent was obtained for every patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}